title: Simultaneous quantitative determinations of fluticasone propionate and salmeterol xinafote in diskus inhalers.
abstract: In the present study, two new methods were developed for the quantitative determination of active components of Seretide(®), commercially available pharmaceutical preparation in the diskus form. One of these methods was based on derivative spectrophotometry and used a zero-crossing technique. The determinations of fluticasone propionate and salmeterol xinafoate were performed by first order derivatisation at 216.5 nm and second order derivatisation at 250 nm, respectively. The concentration ranges were 5.0-32.5 μg/mL for fluticasone propionate and 2-12 μg/mL for salmeterol xinafoate. The second method developed also included high performance liquid chromatography. In this method, a methanol-water mobile phase mixture (95:5, v/v) and a C18 chromasil column as a stationary phase were used. The wavelength of the diode array UV detector was 260 nm; the flow rate was 1 mL/min. The concentration ranges were 2-16 μg/mL for fluticasone propionate and 1-8 μg/mL for salmeterol xinafoate. The results for both methods from diskus are in the pharmacopea limits. For the statistical determination of these results, these two methods were compared with t-test for the means and with F-test for the standard deviations.
authors.forename: A
authors.initials: A
authors.lastname: Duran
authors.forename: H N
authors.initials: HN
authors.lastname: Dogan
authors.affiliation: Acıbadem University Institute of Health Science, Icerenkoy mah., Kayısdagı cad., No:32, Atasehir, Istanbul, Turkey. Ulgen@acibadem.edu.tr.
authors.forename: M
authors.initials: M
authors.lastname: Ulgen
mesh_terms: D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists / Q000008:administration & dosage / Q000032:analysis*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis; D000730:Androstadienes / Q000008:administration & dosage / Q000032:analysis*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000032:analysis*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000032:analysis*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid / Q000592:standards; D004338:Drug Combinations; D058995:Dry Powder Inhalers; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D057230:Limit of Detection; D016014:Linear Models; D012015:Reference Standards; D015203:Reproducibility of Results; D000068299:Salmeterol Xinafoate; D013056:Spectrophotometry, Ultraviolet / Q000592:standards
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol